Spinal Cord Stimulation for Failed Back Surgery Syndrome: to Trial or Not to Trial?
Publication year
2023Source
Journal of Pain, 24, 7, (2023), pp. 1298-1306ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Anesthesiology
Health Evidence
Dentistry
Neurosurgery
Medical Imaging
Journal title
Journal of Pain
Volume
vol. 24
Issue
iss. 7
Page start
p. 1298
Page end
p. 1306
Subject
Radboudumc 0: Other Research Neurosurgery; Radboudumc 10: Reconstructive and regenerative medicine Dentistry; Radboudumc 10: Reconstructive and regenerative medicine Health Evidence; Radboudumc 18: Healthcare improvement science Anesthesiology; Radboudumc 18: Healthcare improvement science Medical Imaging; Neurosurgery - Radboud University Medical CenterAbstract
Spinal cord stimulation (SCS) is a recommended therapy to treat failed back surgery syndrome (FBSS). A trial period is practiced to enhance patient selection. However, its fundamental evidence is limited, especially concerning long-term benefit and therapy safety. We compared the long-term (5.3 ± 4.0 years) clinical outcome and therapy safety of a trialed and nontrialed implantation strategy, including multidimensional variables and pain intensity fluctuations over time. A multicenter cohort analysis was performed in 2 comparable groups of FBSS patients. Regarding eligibility, patients had to be treated with SCS for at least 3 months. While the Trial group comprised patients who underwent an SCS implantation after a successful trial, the No-Trial group encompassed patients who underwent complete implantation within 1 session. The primary outcome measures were pain intensity scores and complications. The Trial and No-Trial groups consisted of 194 and 376 patients (N = 570), respectively. A statistically but not clinically significant difference in pain intensity (P = .003; effect = 0.506 (.172-.839)) was found in favor of the Trial group. No interaction between a time dependency effect and pain intensity was noted. Whereas trialed SCS patients were more likely to cease opioid usage (P = .003; OR = .509 (.326-.792)), patients in the No-Trial group endured fewer infections (P = .006; proportion difference = .43 (.007-.083)). Although the clinical relevance of our findings should be proven in future studies, this long-term real-world data study indicates that patient-centered assessments on whether an SCS trial should be performed have to be investigated. According to the current ambiguous evidence, SCS trials should be considered on a case-by-case basis. PERSPECTIVE: The currently available comparative evidence, together with our results, remains ambiguous on which SCS implantation strategy might be deemed superior. An SCS trial should be considered on a case-by-case basis, for which further investigation of its clinical utility in certain patient populations or character traits is warranted.
This item appears in the following Collection(s)
- Academic publications [246216]
- Electronic publications [133894]
- Faculty of Medical Sciences [93266]
- Open Access publications [107414]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.